Metabolomics Based Study of the Antileishmanial Activity of Xanthium strumarium Leaf Extract on Promastigotes Phases of Leishmania major by Proton NMR Spectroscopy
Background: Xanthium strumarium L. is extensively used as a traditional herb to treat many diseases and is also known as a source of phytochemicals. It has been used traditionally to treat trypanosomiasis, malaria fever, eczema, cancer, ulcer, fever, herpes headache, and skin lesion such as leishmaniasis. In this preliminary study, nuclear magnetic resonance (NMR)-metabolomics approaches was used to evaluate the inhibitory effects and metabolic alterations caused by leaf extract of X. strumarium on the stationary phases of promastigotes in Leishmania major.
Methods: The promastigotes were cultured in Biochemistry Laboratory at Pasteur Institute of Iran in 2017, stationary phases were obtained from 5 to 6 day-old cultures and treated with different concentrations of the plant’s extract. Antileishmanial activity was assayed by MTT method and cell metabolites were extracted. 1H NMR spectroscopy was applied, and outliers were separated using multivariate statistical analysis.
Results: The most affected metabolic pathways in the experimental groups were limited to amino sugar and nucleotide sugar metabolism, cyanoamino acid metabolism, starch and sucrose metabolism, butanoate metabolism, and galactose metabolism.
Conclusion: The ethanolic leaf extract of X. strumarium is a potent growth inhibitor of Leishmania major and can affect vital metabolic pathways of Leishmania promastigotes. The assay provided new perspectives on the development of novel treatment strategies for leishmanial activity derived from natural products.
WHO. Leishmaniasis fact sheet. Geneva Geneva : World Health Organization; 2017.
Canuto GA, da Cruz PL, Faccio AT, Klassen A, Tavares MF. Neglected diseases prioritized in Brazil under the perspective of metabolomics: A review. Electrophoresis. 2015 Jun 10;36(18):2336-47.
Mohebali M. Visceral leishmaniasis in Iran: Review of the Epidemiological and Clinical Features. Iran J Parasitol. 2013 Jul;8(3):348-58. PubMed PMID: 24454426.
Beger RD, Schnackenberg LK, Holland RD, Li DH, Dragan Y. Metabonomic models of human pancreatic cancer using 1D proton NMR spectra of lipids in plasma. Metabolomics. 2006 Sep;2(3):125-34.
Sundar S. Drug resistance in Indian visceral leishmaniasis. Tropical Medicine & International Health. 2001;6(11):849-54.
McConville MJ, Naderer T. Metabolic pathways required for the intracellular survival of Leishmania. Annu Rev Microbiol. 2011;65:543-61.
Gachet MS, Lecaro JS, Kaiser M, Brun R, Navarrete H, Munoz RA, et al. Assessment of anti-protozoal activity of plants traditionally used in Ecuador in the treatment of leishmaniasis. J Ethnopharmacol. 2010 Mar 2;128(1):184-97.
Santin MR, dos Santos AO, Nakamura CV, Dias Filho BP, Ferreira IC, Ueda-Nakamura T. In vitro activity of the essential oil of Cymbopogon citratus and its major component (citral) on Leishmania amazonensis. Parasitol Res. 2009 Nov;105(6):1489-96.
Nibret E, Youns M, Krauth-Siegel RL, Wink M. Biological activities of xanthatin from Xanthium strumarium leaves. Phytother Res. 2011 Dec;25(12):1883-90.
Pandey D, Rather M. Isolation and Identification of Phytochemicals from Xanthium strumarium. Int J ChemTech Res. 2012;4(1):266-71.
Rad JS, Alfatemi SM, Rad MS, Iriti M. In-vitro antioxidant and antibacterial activities of Xanthium strumarium L. extracts on methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Anc Sci Life. 2013 Oct;33(2):109-13.
Talakal TS, Dwivedi SK, Sharma SR. In vitro and in vivo antitrypanosomal activity of Xanthium strumarium leaves. J Ethnopharmacol. 1995 Dec 15;49(3):141-5.
Nadkarni KM, Nadkarni AK. Dr. K.M. Nadkarni's Indian materia medica: with Ayurvedic, Unani-tibbi, Siddha, allopathic, homeopathic, naturopathic & home remedies, appendicces & indexes: Popular Prakashan; 1954.
Dharmananda S. Safety issues affecting Chinese herbs: The case of Xanthium: ITM; 2002.
Chopra RN, Nayar SL, Chopra IC. Glossary of Indian medicinal plants. New Delhi: C SIR. 1956.
Foster S, Duke JA. A field guide to medicinal plants: eastern and central North America: Boston: Houghton Mifflin Company xii, 366p. ISBN; 1990.
Moerman DE. Native American medicinal plants: an ethnobotanical dictionary: Timber Press (OR); 2009.
Oudhia P, Tripathi R, Pandey N, editors. Possibilities of utilization of medicinal weeds to increase the income of the farmers. Abstract National seminar on Medicinal Plant Resources Development Gujarat ayurved University, Gandhi Labour Institute, Ahmedabad; 1998.
Li Y, Chen F, Li Z, Li C, Zhang Y. Identification and functional characterization of sesquiterpene synthases from Xanthium strumarium. Plant and Cell Physiology. 2016;57(3):630-41.
Lavault M, Landreau A, Larcher G, Bouchara JP, Pagniez F, Le Pape P, et al. Antileishmanial and antifungal activities of xanthanolides isolated from Xanthium macrocarpum. Fitoterapia. 2005 Jun;76(3-4):363-6.
Zargari A. Xanthium Strumarium. In: Zargari A, editor. Medicinal Plants. 3. 6 ed. Teharn, Iran: Tehran Univ. ; 1997. p. 207-10.
Eckstein-Ludwig U, Webb R, Van Goethem I, East J. Artemisinins target the SERCA of Plasmodium falciparum. Nature. 2003;424(6951):957.
Ramírez-Erosa I, Huang Y, Hickie RA, Sutherland RG, Barl B. Xanthatin and xanthinosin from the burs of Xanthium strumarium L. as potential anticancer agents This article is one of a selection of papers published in this special issue (part 2 of 2) on the Safety and Efficacy of Natural Health Products. Canadian journal of physiology and pharmacology. 2007;85(11):1160-72.
Bremner P, Heinrich M. Natural products as targeted modulators of the nuclear factor‐KB pathway. Journal of Pharmacy and Pharmacology. 2002;54(4):453-72.
Drew DP, Dueholm B, Weitzel C, Zhang Y, Sensen CW, Simonsen HT. Transcriptome analysis of Thapsia laciniata Rouy provides insights into terpenoid biosynthesis and diversity in Apiaceae. International journal of molecular sciences. 2013;14(5):9080-98.
Subramanian A, Jhawar J, Sarkar RR. Dissecting leishmania infantum energy metabolism-a systems perspective. PloS one. 2015;10(9):e0137976.
Brennand A, Gualdrón-López M, Coppens I, Rigden DJ, Ginger ML, Michels PA. Autophagy in parasitic protists: unique features and drug targets. Molecular and biochemical parasitology. 2011;177(2):83-99.
Silva AM, Cordeiro-da-Silva A, Coombs GH. Metabolic variation during development in culture of Leishmania donovani promastigotes. PLoS neglected tropical diseases. 2011;5(12):e1451.
Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clinical microbiology reviews. 2006;19(1):111-26.
Berg M, Garcia-Hernandez R, Cuypers B, Vanaerschot M, Manzano JI, Poveda JA, et al. Experimental resistance to drug combinations in Leishmania donovani: metabolic and phenotypic adaptations. Antimicrob Agents Chemother. 2015 Apr;59(4):2242-55. PubMed PMID: 25645828.
Swanepoel CC, Loots DT. The use of functional genomics in conjunction with metabolomics for Mycobacterium tuberculosis research. Disease markers. 2014;2014.
Vincent IM, Barrett MP. Metabolomic-based strategies for anti-parasite drug discovery. Journal of biomolecular screening. 2015;20(1):44-55.
Scherer R, Godoy H. Effects of extraction methods of phenolic compounds from Xanthium strumarium L. and their antioxidant activity. Revista Brasileira de Plantas Medicinais. 2014;16(1):41-6.
Brenzan MA, Nakamura CV, Dias Filho BP, Ueda-Nakamura T, Young MCM, Cortez DAG. Antileishmanial activity of crude extract and coumarin from Calophyllum brasiliense leaves against Leishmania amazonensis. Parasitology research. 2007;101(3):715-22.
Salehabadi A, Karamian M, Farzad MH, Namaei MH. Effect of root bark extract of Berberis vulgaris L. on Leishmania major on BALB/c mice. Parasitology research. 2014;113(3):953-7.
Wang X, Ge J, Wang K, Qian J, Zou Y. Evaluation of MTT assay for measurement of emodin-induced cytotoxicity. Assay and drug development technologies. 2006;4(2):203-7.
Gupta N, Goyal N, Singha UK, Bhakuni V, Roy R, Rastogi AK. Characterization of intracellular metabolites of axenic amastigotes of Leishmania donovani by 1H NMR spectroscopy. Acta Trop. 1999 Jul 30;73(2):121-33. PubMed PMID: 10465052.
Sheedy JR. Metabolite analysis of biological fluids and tissues by proton nuclear magnetic resonance spectroscopy. Methods Mol Biol. 2013;1055:81-97.
Viant MR. Improved methods for the acquisition and interpretation of NMR metabolomic data. Biochemical and biophysical research communications. 2003;310(3):943-8.
Xia J, Sinelnikov IV, Han B, Wishart DS. MetaboAnalyst 3.0—making metabolomics more meaningful. Nucleic acids research. 2015;43(W1):W251-W7.
Damerow S, Hoppe C, Bandini G, Zarnovican P, Buettner FF, Ferguson MA, et al. Leishmania major UDP-sugar pyrophosphorylase salvages galactose for glycoconjugate biosynthesis. Int J Parasitol. 2015 Oct;45(12):783-90.
Naderer T, Heng J, Saunders EC, Kloehn J, Rupasinghe TW, Brown TJ, et al. Intracellular Survival of Leishmania major Depends on Uptake and Degradation of Extracellular Matrix Glycosaminoglycans by Macrophages. PLoS Pathog. 2015 Sep;11(9):e1005136.
Zhang W-W, Chan KF, Song Z, Matlashewski G. Expression of a Leishmaniadonovani nucleotide sugar transporter in Leishmaniamajor enhances survival in visceral organs. Experimental parasitology. 2011;129(4):337-45.
Rodríguez-Contreras D, Landfear SM. Metabolic changes in glucose transporter-deficient Leishmania mexicana and parasite virulence. Journal of Biological Chemistry. 2006;281(29):20068-76.
Capul AA, Hickerson S, Barron T, Turco SJ, Beverley SM. Comparisons of mutants lacking the Golgi UDP-galactose or GDP-mannose transporters establish that phosphoglycans are important for promastigote but not amastigote virulence in Leishmania major. Infection and immunity. 2007;75(9):4629-37.
Oppenheimer M, Valenciano AL, Sobrado P. Biosynthesis of galactofuranose in kinetoplastids: novel therapeutic targets for treating leishmaniasis and Chagas' disease. Enzyme research. 2011;2011.
Gaur U, Showalter M, Hickerson S, Dalvi R, Turco SJ, Wilson ME, et al. Leishmania donovani lacking the Golgi GDP-Man transporter LPG2 exhibit attenuated virulence in mammalian hosts. Exp Parasitol. 2009 Jul;122(3):182-91.
Späth GF, Lye L-F, Segawa H, Sacks DL, Turco SJ, Beverley SM. Persistence without pathology in phosphoglycan-deficient Leishmania major. Science. 2003;301(5637):1241-3.
Meshram RJ, Jangle, SN. Comparative metabolomic investigation of leishmania major and homo sapiens: an in-silico technique to discover and develop novel drug targets. Pharmacophore 2011;2 (2):98-107.
Singh J, Srivastava A, Jha P, Sinha KK, Kundu B. L-Asparaginase as a new molecular target against leishmaniasis: insights into the mechanism of action and structure-based inhibitor design. Molecular BioSystems. 2015;11(7):1887-96.
George SS, Bishop JV, Titus RG, Selitrennikoff CP. Novel compounds active against Leishmania major. Antimicrobial agents and chemotherapy. 2006;50(2):474-9.
Opperdoes FR, Michels PA. The metabolic repertoire of Leishmania and implications for drug discovery. Leishmania, after the Genome. 2008:123-58.
Faria J, Loureiro I, Santarém N, Macedo-Ribeiro S, Tavares J, Cordeiro-da-Silva A. Leishmania infantum asparagine synthetase A is dispensable for parasites survival and infectivity. PLoS neglected tropical diseases. 2016;10(1):e0004365.
Jacobson RL, Schlein Y. Phlebotomus papatasi and Leishmania major parasites express α-amylase and α-glucosidase. Acta tropica. 2001;78(1):41-9.
Tielens AG, van Hellemond JJ. Surprising variety in energy metabolism within Trypanosomatidae. Trends in parasitology. 2009;25(10):482-90.
Santos DCM, Lima ML, Toledo JS, Fernandes PA, Aguiar MMG, Lopez-Gonzalvez A, et al. Metabolomics as a tool to evaluate the toxicity of formulations containing amphotericin B, an antileishmanial drug. Toxicology Research. 2016;5(6):1720-32.
McConville M, Turco S, Ferguson M, Sacks D. Developmental modification of lipophosphoglycan during the differentiation of Leishmania major promastigotes to an infectious stage. The EMBO journal. 1992;11(10):3593.
Damerow S, Lamerz A-C, Haselhorst T, Führing J, Zarnovican P, von Itzstein M, et al. Leishmania UDP-sugar pyrophosphorylase the missing link in galactose salvage? Journal of Biological Chemistry. 2010;285(2):878-87.
Ilgoutz SC, McConville MJ. Function and assembly of the Leishmania surface coat. International journal for parasitology. 2001;31(9):899-908.
Puentes SM, Da Silva RP, Sacks DL, Hammer CH, Joiner KA. Serum resistance of metacyclic stage Leishmania major promastigotes is due to release of C5b-9. The Journal of Immunology. 1990;145(12):4311-6.
Sacks DL. Metacyclogenesis in Leishmania promastigotes. Experimental parasitology. 1989;69(1):100-3.
Kleczka B, Lamerz AC, van Zandbergen G, Wenzel A, Gerardy-Schahn R, Wiese M, et al. Targeted gene deletion of Leishmania major UDP-galactopyranose mutase leads to attenuated virulence. J Biol Chem. 2007 Apr 6;282(14):10498-505.
Roper JR, Güther MLS, Milne KG, Ferguson MA. Galactose metabolism is essential for the African sleeping sickness parasite Trypanosoma brucei. Proceedings of the National Academy of Sciences. 2002;99(9):5884-9.
|Issue||Vol 14 No 2 (2019)|
|Xanthium Strumarium Leishmania major NMR spectroscopy Metabolomics|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|